BRIM Biotechnology, Inc. (TPE:6885)

Market Cap	3.18B -20.6%
Revenue (ttm)	5.49M +1,548.6%
Net Income	-436.45M
EPS	-3.32
Shares Out	133.21M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	282,359
Average Volume	373,331
Open	23.25
Previous Close	23.95
Day's Range	23.25 - 23.95
52-Week Range	20.05 - 41.30
Beta	1.03
RSI	30.47
Earnings Date	May 8, 2026

About BRIM Biotechnology

BRIM Biotechnology, Inc. engages in the research and development of drugs and therapies to combat and cure diseases in Taiwan. The company’s lead product candidate is BRM421, a neurotrophic peptide which has completed a Phase 3 clinical trial for the treatment of dry eye disease. It is also developing BRM424, a treatment option that has completed Phase 1 clinical trial for neurotrophic keratitis; BRM411, a dual target inhibitor, which has completed Phase 2 clinical trial for the treatment of glaucoma; BRM412, an anti-angiogenic eye drop that ha...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 32
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 6885

Financial Performance

In 2025, BRIM Biotechnology's revenue was 5.49 million, an increase of 1548.65% compared to the previous year's 333,000. Losses were -436.45 million, 38.3% more than in 2024.